Gaithersburg, Maryland, June 20, 2025 (Glove Newswire) – Bullfrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“Bullfrog AI” or “Company”), a technology-enabled drug development company using artificial intelligence (AI), and currently Machine Learning AI, Machine Learning, and Innovation to carry out machine learning that enables the development of successful biology at Jusutical will become the hot topic speakers to overcome the pitfalls of the upcoming Xtalks Webinar: AI in Bioinformatics: Statistics, ML, and Generation AI approach.
Vin Singh, Founder and CEO of Bullfrog AI, highlights that Dr. Beltrán's participation in Xtalks Webinar not only highlights our leadership position in AI-driven bioinformatics, but also impacts important scientific challenges that directly affect important scientific challenges that directly affect the commitment of Bullfrog AI. Introducing the innovative capabilities of Bullfrog AI will support our strategic vision and strengthen our position within this rapidly growing sector.”
Join Dr. Juan Felipe Beltrán, a leading scientist and software engineer with deep expertise in machine learning, algorithm development and bioinformatics. Dr. Beltrán draws on extensive contributions to public health challenges like proteomics, genomics, and Covid-19 to emphasize that even sophisticated calculation methods can be circulated around without paying attention to analytical nuances.
This session will focus on improving the accuracy and reproducibility of bioinformatics analysis by addressing three key issues: mismanagement of compositional data, overinterpretation of the importance of machine learning features, and misuse of generated AI for biological rankings and prioritization. Participants will gain practical insights to strengthen their data science foundations, improve the reliability of AI models, and to make bioinformatics strategies into the future in an increasingly complex research environment.
Dr. Bertrand's track record in advancing complex bioinformatics solutions greatly enhances Bullfrog AI's proprietary Bfleap™ platform and flagship Bullfrog Data Networks™. Bullfrog AI's solution directly addresses the critical challenges of biological disorders, with only 12% of drugs participating in phase 1 clinical trials reaching the market.
Interested experts, including bioinformaticians, biostatisticians, data scientists and translation scientists, are encouraged to acquire practical strategies to mitigate the pitfalls of AI-powered bioinformatics workflows, and ultimately acquire practical strategies to improve decision-making and increase confidence in the results of analysis.
About Bullfrog AI
Bullfrog AI leverages artificial intelligence and machine learning to advance drug discovery and development. Through collaboration with leading research institutes, Bullfrog AI aims to analyze complex biological data using causal AI in conjunction with its proprietary Bfleap™ platform, streamline the development of clinical trials and reduce failure rates.
For more information, please visit Bullfrog AI at https://bulfrogai.com
A safe port statement
This press release contains forward-looking statements. We build on these forward-looking statements based on expectations and forecasts regarding future events derived from information currently available. Such forward-looking statements relate to future performance, including future events or: Our financial performance and forecasts. Our revenue and revenue. And our business outlook and opportunities. Forward-looking statements can be identified by those who are not inherently historic, in particular terms such as “May,” “potential,” “will,” “expected,” “expected,” “estimate,” “believe,” “plan,” “predictions,” “predictions,” “predictions,” “potential,” “potential,” or “hope,” or “hope,” or negative terms. When evaluating these forward-looking statements, various factors should be taken into consideration, including: Ability to meet new technologies and market needs. The sales and sales capabilities of our company and our partners, including Bullfrog Data Networks™ and the competitive environment of our business. Due to these and other factors, actual results may differ materially from forward-looking statements. Forward-looking statements are forecasts only. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives may not occur, and actual events and outcomes may differ materially and are subject to risks, uncertainties and assumptions relating to us. We have no obligation to publicly update or amend our forward-looking statements, whether or not the future-looking events discussed in this press release and other statements made from time to time by us or our representatives, as a result of uncertainty and assumptions, may not arise.
contact:
Dave Gentry
Redchip Companies, Inc.
1-407-644-4256
bfrg@redchip.com
